Gilead May Face Uphill Task With Sovaldi Despite Voluntary License Plan With Indian Generic Firms
This article was originally published in PharmAsia News
Executive Summary
Gilead may face unexpected speed bumps related to Sovaldi patents in India as it tries to extend the reach of its breakthrough HCV treatment via a combination of strategies, including voluntary licenses with Indian generics firms.